Revance to Participate in the Needham Healthcare Conference

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference in New York, NY.

Chief Financial Officer and Chief Business Officer, Lauren Silvernail, is scheduled to present on Tuesday, March 27 at 8:00am ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180320005124/en/

INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
[email protected]
or
Burns McClellan, Inc.:
Ami Bavishi, 212-213-0006
[email protected]
or
MEDIA
General Media:
TOGORUN:
Mariann Caprino, 917-242-1087
[email protected]
or
Trade Media:
Nadine Tosk, 504-453-8344
[email protected]

Source: Revance Therapeutics, Inc.

You May Also Be Interested In

• GFL Environmental Joins the Russell 1000® and Russell 3000® Indices
• FLORIDA CANYON FEASIBILITY STUDY DELIVERS SUBSTANTIAL INCREASE IN MINERAL RESERVE, GOLD PRODUCTION OVER AN 8-YEAR MINE LIFE AND US$0.8 BILLION IN AFTER-TAX FREE CASH FLOW; PROVIDES OPERATIONAL UPDATE
• Dimensional Fund Advisors Ltd. : Form 8.3 - ADVANCED MEDICAL SOLUTIONS - Ordinary Shares